Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > REGULATORY
REGULATORY
- MHLW Stresses the Importance of Maintaining Quality of GMP Inspections Following Japan’s Accession to PIC/S
March 3, 2014
- PMDA Begins Disclosing Information on ADRs Reported by Patients through Online Patient ADR Reporting System
February 28, 2014
- Ministry Joint Panel Says Evidence Linking HPV Vaccine Adjuvant with Side Effects Weak
February 27, 2014
- Ethics Code for Epidemiological, Clinical Research to Call for COI Management, Whistle-Blowing: Draft
February 27, 2014
- PFSB Issues Notification on Marketing Authorization Applications for In Vitro Companion Diagnostics
February 27, 2014
- US FDA, EMA Hold Monthly Regulatory Working-Level Talks, with Participation of PMDA as Observer
February 27, 2014
- EMA Recommends Approval for Fixed-Dose Combination of Canagliflozin, Metformin
February 27, 2014
- Cabinet OKs Bill to Merge NIBIO, NIHN to Create New Institute
February 26, 2014
- PAFSC’s First Committee Supports Approval of Novel Antiplatelet Agent Prasugrel
February 25, 2014
- Penalty for Lengthy Drug Delivery Talks Will Lift Price Settlement Rates: Minister
February 25, 2014
- MHLW May Take Harsh Action against Novartis over Diovan Raids: Minister Tamura
February 25, 2014
- LDP Closes Discussions on Fee Cuts to Be Imposed on Hospitals, Pharmacies with Low Price Settlement Rates
February 25, 2014
- MHLW to Set Up Complaint Hotline for Hospitals, Pharmacies Upon Introduction of Penalty for Low Price Settlement Rates
February 25, 2014
- Astellas Unit, 12 Others Prequalified for Expedited Product Importation under FDA Pilot Program
February 21, 2014
- PFSB Issues Director Notification Calling for Revision of Package Inserts for Products Including Kiklin, Stivarga
February 20, 2014
- Tokyo Prosecutors Raid Novartis Japan Office over Diovan Ads
February 20, 2014
- Penalty for Lengthy Drug Price Haggling – Interview 1: “It Can’t Be Helped” Says Idaikyo Exec Koyama
February 19, 2014
- MHLW to Form Panel to Combat Counterfeit Drugs
February 19, 2014
- Deputy Director Masuyama of ELD Stresses Need to Establish Separate Guidelines for Different Biosimilars at SRSM Symposium
February 19, 2014
- PAFSC Second Committee to Discuss H5N1 Vaccines on Feb. 28
February 18, 2014
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…